The revenue miss and deteriorating adjusted EBITDA signal that the BARDA contract transition is pressuring near-term financials more than expected, but the FDA clearance and reiterated guidance suggest management sees a clear path to commercial revenue by year-end. Traders should watch for any pre-announcement of first DeepView System sales or BARDA contract extensions, as these are the primary catalysts for the stock given the current pre-commercial revenue base.
Price Chart
Executive Summary
Spectral AI reported Q2 2026 results with R&D revenue declining to $3.5M (from $5.1M YoY) as BARDA contract work narrowed post-FDA clearance, and operating expenses rising 23% to $5.4M as the company invests in commercial infrastructure ahead of first DeepView System sales by year-end 2026. Net loss improved to -$4.2M (-$0.13/share) from -$8.0M (-$0.31/share) in Q2 2025, driven by a $0.7M favorable warrant liability swing vs a -$5.4M charge last year, but adjusted EBITDA worsened to -$3.5M from -$1.7M. The company reiterated $18.5M full-year 2026 revenue guidance excluding any commercial DeepView sales, maintaining a $14.0M cash position after drawing $6.5M from its credit facility post-FDA clearance in May 2026.
Key Financial Metrics
Key Facts
- Q2 2026 R&D revenue $3.5M vs $5.1M YoY, down 31% due to BARDA contract cost-share phase and MTEC completion
- Gross margin fell to 31.6% from 45.2% YoY due to cost-share provisions under the BARDA follow-on development phase
- Operating expenses rose 23.2% to $5.4M, with selling & marketing up $0.3M ahead of first commercial sales
- Net loss improved to -$4.2M (-$0.13/share) from -$8.0M (-$0.31/share) YoY, primarily on a $0.7M favorable warrant liability swing
- Adjusted EBITDA worsened to -$3.5M from -$1.7M YoY, reflecting lower gross profit and higher operating spend
- Cash $14.0M at June 30, 2026 vs $15.4M at Dec 31, 2025; drew $6.5M from Avenue Capital credit facility post-FDA clearance
- Reiterated 2026 revenue guidance of ~$18.5M, excluding any commercial DeepView System sales
- Received FDA De Novo clearance for DeepView System in May 2026; first commercial sales targeted by year-end 2026
- EPS of -$0.13 beat consensus of -$0.14 by 7.1%
- Revenue of $3.5M missed consensus of $4.2M by 16.7%
Financial Impact
Revenue miss of ~$0.7M vs consensus; EPS beat of $0.01 vs consensus; cash burn of $1.4M in H1 2026
Risk Factors
- Commercial DeepView System sales may not materialize by year-end 2026 as guided
- Cash burn of $7.8M in H1 2026 from operations could require additional financing before commercial revenue ramps
- BARDA contract cost-share phase reduces gross margins and may continue to pressure profitability
- Warrant liability fair value changes create significant GAAP earnings volatility unrelated to operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-088341 |
| Document: ea0301807-8k_spectral.htm | 0001213900-26-088341 |
| Document: 0001213900-26-088341-index-headers.html | 0001213900-26-088341 |
| Document: 0001213900-26-088341-index.html | 0001213900-26-088341 |
| Document: 0001213900-26-088341.txt | 0001213900-26-088341 |
| 8-K Data (Synthetic) | 0001213900-26-088341 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 10w ago | 8-K | $1.73 | awaiting T+60 | — | $1.53 (−11.56%) |
Jul 8, 2026 15w ago | 8-K | $1.72 $1.66 | ▼ −3.49% | ▼ −5.12% | $1.53 (−11.05%) |
Mar 24, 2026 30w ago | Press Release | $1.54 $1.76 | ▲ +14.15% | ▲ +0.69% | $1.53 (−0.65%) |
Mar 18, 2026 31w ago | Press Release | $1.42 $1.84 | ▲ +29.58% | ▲ +15.23% | $1.53 (+7.75%) |
Mar 10, 2026 33w ago | Press Release | $1.40 $1.94 | ▲ +38.57% | ▲ +26.89% | $1.53 (+9.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers